TY - JOUR
T1 - Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST)
T2 - a US qualitative analysis
AU - Shlobin, Oksana A.
AU - Bruce, Gary
AU - Gomez-Rendon, Gabriela
AU - Kingman, Martha
AU - Rahman, Mohammad
AU - Rogers, Frances
AU - Studer, Sean
AU - Tobore, Tobore
AU - McEvoy, Colleen
N1 - Publisher Copyright:
© 2024 Actelion Pharmaceuticals US, Inc. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute.
PY - 2024/10
Y1 - 2024/10
N2 - This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.
AB - This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.
KW - healthcare professional discussion tool
KW - patient perspectives
KW - pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=85206246270&partnerID=8YFLogxK
U2 - 10.1002/pul2.12441
DO - 10.1002/pul2.12441
M3 - Letter
C2 - 39398324
AN - SCOPUS:85206246270
SN - 2045-8932
VL - 14
JO - Pulmonary Circulation
JF - Pulmonary Circulation
IS - 4
M1 - e12441
ER -